CASSAVA SCIENCES INC — Investor Relations & Filings
Filings indexed
1,004
across all filing types
Latest filing
2026-05-07
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
SAVA
Cassava Sciences, Inc. is a clinical-stage biotechnology company that develops investigational treatments for Central Nervous System (CNS) disorders. The company's primary focus is on its lead drug candidate, simufilam, a proprietary oral small molecule. Simufilam is designed to modulate the activity of the filamin A (FLNA) protein, which is involved in regulating neuronal development. The development program for simufilam targets conditions such as tuberous sclerosis complex (TSC)-related epilepsy and other mTOR pathway disorders. Preclinical studies in TSC models have shown that simufilam may reduce seizure frequency, supporting plans for future clinical trials.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | |
| 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | |
| 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-04-28 | English | |
| 8-K - CASSAVA SCIENCES INC (0001069530) (Filer) | 2026-02-19 | English | |
| FORM 8-K | 2025-12-23 | English | |
| FORM 8-K/A | 2025-12-22 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 43596105 | 10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | ||
| 42914481 | 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | ||
| 38155638 | 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-04-28 | English | ||
| 32886944 | 8-K - CASSAVA SCIENCES INC (0001069530) (Filer) | 2026-02-19 | English | ||
|
2025
11 filings
| |||||
| 11109579 | FORM 8-K | 2025-12-23 | English | ||
| 11109585 | FORM 8-K/A | 2025-12-22 | English | ||
| 11109591 | FORM 8-K | 2025-12-18 | English | ||
| 11109619 | FORM 8-K | 2025-12-17 | English | ||
| 11109593 | Regulatory Filings 2025 | 2025-12-08 | English | ||
| 11109595 | 424B2 | 2025-12-05 | English | ||
| 11109620 | FORM 8-K | 2025-12-03 | English | ||
| 11109618 | FORM 4 | 2025-11-25 | English | ||
| 11109599 | FORM 4 | 2025-11-24 | English | ||
| 11109601 | FORM 4 | 2025-11-20 | English | ||
| 11109622 | S-3 | 2025-11-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Matinas BioPharma Holdings, Inc.
Biopharma firm developing therapeutics using its Lipid Nano…
|
MTNB | US | Professional, scientific and te… |
|
Matricelf Ltd.
Develops autologous, patient-specific tissue implants for r…
|
MTLF | IL | Professional, scientific and te… |
|
MAXCYTE, INC.
A cell-engineering company with a platform for developing c…
|
MXCT | US | Professional, scientific and te… |
|
Medicenna Therapeutics Corp.
A clinical-stage immunotherapy company developing novel eng…
|
MDNA | CA | Professional, scientific and te… |
|
Medicofarma Biotech Spolka Akcyjna
R&D company developing innovative medicines, medical device…
|
MDB | PL | Professional, scientific and te… |
|
Medigene AG
Develops TCR-guided immunotherapies for cancer; currently i…
|
MDG1 | DE | Professional, scientific and te… |
|
Medizen Humancare Inc Co., Ltd
A research company specializing in genomic analysis for per…
|
236340 | KR | Professional, scientific and te… |
|
Medpace Holdings, Inc.
A global CRO providing Phase I-IV clinical development for …
|
MEDP | US | Professional, scientific and te… |
|
MegaPro Biomedical Co. Ltd.
A clinical-stage biotech developing nanomedicines for oncol…
|
— | MY | Professional, scientific and te… |
|
MEMPHASYS LIMITED.
Develops cell separation solutions for human and animal rep…
|
MEM | AU | Professional, scientific and te… |
CASSAVA SCIENCES INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33903/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33903 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33903 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33903 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33903}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CASSAVA SCIENCES INC (id: 33903)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.